论文部分内容阅读
目的 :观察柳氮磺胺嘧啶 ( SASP)对强直性脊柱炎的早期疗效 ,探讨其作用机理。方法 :选择 61例强直性脊柱炎的 ( AS)患者 ,随机分为两组 ,排除强直性脊柱炎以外疾病。其中 SASP组 2 9例 ,NSAIDs组 32例进行疗效观察。结果 :治疗 6个月 ,晨僵时间、关节疼痛数和血沉在两组间有显著的差异( P<0 .0 5 )。在 SASP组临床缓解、显效、有效和无效率分别为 41 %、2 8%、2 1 %和 1 0 % ;在 NSAIDs组分别为 9%、34%、31 %和 2 5 %。结论 :SASP对早、中期强直性脊柱炎有良好的治疗效果 ,并可终止或延缓病情进展 ,减少脊椎关节僵硬等并发症。
Objective: To observe the early curative effect of sulfasalazine (SASP) on ankylosing spondylitis and to explore its mechanism. Methods: Sixty-one patients with ankylosing spondylitis (AS) were selected and randomly divided into two groups to exclude diseases other than ankylosing spondylitis. 29 cases in SASP group and 32 cases in NSAIDs group were observed. Results: After 6 months of treatment, morning stiffness, joint pain and ESR were significantly different between the two groups (P <0.05). In the SASP group, clinical remission, effective, effective and ineffective rates were 41%, 28%, 21% and 10%, respectively; in the NSAIDs group 9%, 34%, 31% and 25%, respectively. Conclusion: SASP has good therapeutic effect on early and middle ankylosing spondylitis, and can stop or delay the progression of the disease and reduce complications such as stiffness of the spine.